WEBSTER, Texas, Oct. 21 /PRNewswire/ -- IDEV Technologies, Incorporated (IDEV), an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced another step in the implementation of its strategy to expand its product line for treating patients with peripheral vascular disease with the addition of two longer stents to its SUPERA product line. The initial uses of the newly introduced 180mm and 200mm stents occurred in August of this year, followed by a full European market launch at the recent European Society of Vascular Surgery meeting held this past September, in Amsterdam.
SUPERA stents are well known for their radial strength and flexibility that results from the unique wire interwoven nitinol design, which also provides high resistance to kinking/fracturing. The new 180mm and 200mm sizes are designed for the treatment of long lesions in patients with peripheral vascular disease.
"We are very pleased with the acceptance of these new longer stents. Our goal is to provide the broadest and most effective line of products for treating patients with peripheral vascular disease. The successful launch of these additional SUPERA sizes moves us closer to reaching that goal and achieves our objective of launching multiple new products in Europe this year," stated Christopher M. Owens, President and CEO of IDEV.
The launch of these devices follows the recent introduction of the SUPERA VERITAS™ Peripheral Vascular System, an easy to use, reliable and more precise delivery system developed to deliver the SUPERA stent.
Peter Haarbrink, MD, a leading interventional radiologist affiliated with Canisius Wilhelmina Ziekenhuis (CWZ), a large general and teaching hospital located in Nijmegen, The Netherlands, said, "The availability of these new sizes has given me even more options for treating patients with peripheral vascular disease. The unique and exceptional st